Daniel D. Mikol

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby, Uwe Reuter, Yngve Hallström et al. · New England Journal of Medicine · 2017 · 911 citations · Full text

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

Stewart J. Tepper, Messoud Ashina, Uwe Reuter et al. · The Lancet Neurology · 2017 · 726 citations

Chronic Migraine, Placebo-controlled Phase 2, Cluster Headache +7

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

David W. Dodick, Messoud Ashina, Jan Lewis Brandes et al. · Cephalalgia · 2018 · 570 citations

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Daniel D. Mikol, Frederik Barkhof, Peter Chang et al. · The Lancet Neurology · 2008 · 480 citations

Autoimmune Disease, Disease Progression, Neurological Disorder +8

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Ludwig Kappos, Hans‐Peter Hartung, Mark S. Freedman et al. · The Lancet Neurology · 2014 · 325 citations

Neurological Disorder, Pain Medicine, Medicine +7